{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:29:09Z","timestamp":1790710149312,"version":"4.1.0"},"reference-count":124,"publisher":"Portland Press Ltd.","issue":"02","license":[{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,8]]},"abstract":"<jats:p>Vaccination remains a cornerstone in preventing infectious diseases and managing outbreaks. The COVID-19 pandemic has underscored the revolutionary impact of mRNA vaccine technology, which utilizes pathogenderived genomic sequences to generate specific antigens. This process involves in vitro transcription of mRNA, encoding target antigens that are subsequently encapsulated within lipid nanoparticles (LNPs) for efficient delivery into host cells. Once internalized, the mRNA enables antigen expression, triggering a robust immune response. This platform dramatically accelerates vaccine development timelines and offers unparalleled adaptability, making mRNA vaccines particularly advantageous in addressing emerging infectious diseases. The clinical success of BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) has fueled broader applications, including influenza, respiratory syncytial virus (RSV), Zika, and HIV. Notably, mRNA-1345 became the first FDA-approved RSV mRNA vaccine, while self-amplifying RNA and multivalent vaccines are advancing in trials. However, CureVac\u2019s CVnCoV failed due to lack of nucleoside modifications, and mRNA-1325 (Zika) showed poor immunogenicity. Additionally, mRNA-1365 (RSV) faced an FDA clinical hold due to safety concerns. These cases highlight the need for continued optimization in sequence design, delivery, and safety assessment. Despite advancements, a key hurdle persists, including mRNA instability, ultra-low storage requirements, and LNP liver accumulation. Innovations such as lyophilization and selective organ targeting technology are being explored to improve stability extrahepatic delivery. This review examines mRNA vaccine optimization strategies, clinical progress, and challenges, providing insights into future developments in this evolving field.<\/jats:p>","DOI":"10.1042\/ebc20253009","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T04:00:36Z","timestamp":1746417636000},"page":"109-131","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Advancing mRNA vaccines for infectious diseases: key components, innovations, and clinical progress"],"prefix":"10.1042","volume":"69","author":[{"given":"Sha","family":"Li","sequence":"first","affiliation":[{"name":"1Shanghai Pudong Hospital, Key Laboratory of Medical Molecular Virology (MOE\/NHC\/CAMS), School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zheng","sequence":"additional","affiliation":[{"name":"2Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Zhong","sequence":"additional","affiliation":[{"name":"1Shanghai Pudong Hospital, Key Laboratory of Medical Molecular Virology (MOE\/NHC\/CAMS), School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2149-0008","authenticated-orcid":false,"given":"Xihui","family":"Gao","sequence":"additional","affiliation":[{"name":"1Shanghai Pudong Hospital, Key Laboratory of Medical Molecular Virology (MOE\/NHC\/CAMS), School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, China"},{"name":"2Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2025,5,1]]},"reference":[{"key":"2025090902071103800_EBC-2025-3009C1","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.vaccine.2023.07.033","article-title":"Modeling the impact of vaccination for the immunization agenda 2030: deaths averted due to vaccination against 14 pathogens in 194 countries from 2021 to 2030","volume":"42","author":"Carter","year":"2024","journal-title":"Vaccine"},{"key":"2025090902071103800_EBC-2025-3009C2","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2022.105828","article-title":"Novel coronavirus mutations: vaccine development and challenges","volume":"173","author":"Luo","year":"2022","journal-title":"Microb. Pathog."},{"key":"2025090902071103800_EBC-2025-3009C3","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines11071264","article-title":"The promising potential of reverse vaccinology-based next-generation vaccine development over conventional vaccines against antibiotic-resistant bacteria","volume":"11","author":"Khalid","year":"2023","journal-title":"Vaccines"},{"key":"2025090902071103800_EBC-2025-3009C4","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/s41565-023-01347-w","article-title":"mRNA therapy at the convergence of genetics and nanomedicine","volume":"18","author":"Conde","year":"2023","journal-title":"Nat. Nanotechnol."},{"key":"2025090902071103800_EBC-2025-3009C5","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.biomaterials.2017.11.034","article-title":"Emergence of synthetic mRNA: in vitro synthesis of mRNA and its applications in regenerative medicine","volume":"156","author":"Kwon","year":"2018","journal-title":"Biomaterials"},{"key":"2025090902071103800_EBC-2025-3009C6","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1039\/D3CS00194F","article-title":"Nucleic acid degradation as barrier to gene delivery: a guide to understand and overcome nuclease activity","volume":"53","author":"Zhang","year":"2024","journal-title":"Chem. Soc. Rev."},{"key":"2025090902071103800_EBC-2025-3009C7","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1021\/acs.molpharmaceut.3c00439","article-title":"Complex coacervates as a promising vehicle for mRNA delivery: a comprehensive review of recent advances and challenges","volume":"20","author":"Forenzo","year":"2023","journal-title":"Mol. Pharm."},{"key":"2025090902071103800_EBC-2025-3009C8","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/s41573-024-00977-6","article-title":"The 60-year evolution of lipid nanoparticles for nucleic acid delivery","volume":"23","author":"Cullis","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"2025090902071103800_EBC-2025-3009C9","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14030543","article-title":"Methods of liposomes preparation: formation and control factors of versatile nanocarriers for biomedical and nanomedicine application","volume":"14","author":"Lombardo","year":"2022","journal-title":"Pharmaceutics"},{"key":"2025090902071103800_EBC-2025-3009C10","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.addr.2020.07.002","article-title":"Liposomes: advancements and innovation in the manufacturing process","volume":"154","author":"Shah","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2025090902071103800_EBC-2025-3009C11","first-page":"1","article-title":"A historical overview on mRNA vaccine development","author":"Verbeke","year":"2025","journal-title":"Trends mRNA Vaccine Res"},{"key":"2025090902071103800_EBC-2025-3009C12","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114432","article-title":"The growth of siRNA-based therapeutics: updated clinical studies","volume":"189","author":"Zhang","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"2025090902071103800_EBC-2025-3009C13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/17425247.2023.2162876","article-title":"Why mRNA-ionizable LNPs formulations are so short-lived: causes and way-out","volume":"20","author":"De","year":"2023","journal-title":"Expert Opin. Drug Deliv."},{"key":"2025090902071103800_EBC-2025-3009C14","doi-asserted-by":"crossref","first-page":"5672","DOI":"10.1021\/acs.molpharmaceut.4c00628","article-title":"Effect of anti-PEG antibody on immune response of mRNA-loaded lipid nanoparticles","volume":"21","author":"Omata","year":"2024","journal-title":"Mol. Pharm."},{"key":"2025090902071103800_EBC-2025-3009C15","doi-asserted-by":"crossref","first-page":"11467","DOI":"10.1038\/s41598-024-61922-6","article-title":"Antibody longevity and waning following COVID-19 vaccination in a 1-year longitudinal cohort in Bangladesh","volume":"14","author":"Haq","year":"2024","journal-title":"Sci. Rep."},{"key":"2025090902071103800_EBC-2025-3009C16","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2022.27.2.2101197","article-title":"Waning antibody levels after COVID-19 vaccination with mRNA comirnaty and inactivated coronavac vaccines in blood donors, Hong Kong, April 2020 to October 2021","volume":"27","author":"Kwok","year":"2022","journal-title":"Euro Surveill."},{"key":"2025090902071103800_EBC-2025-3009C17","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.immuni.2022.10.014","article-title":"Innate immune mechanisms of mRNA vaccines","volume":"55","author":"Verbeke","year":"2022","journal-title":"Immunity"},{"key":"2025090902071103800_EBC-2025-3009C18","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens12010138","article-title":"Self-amplifying RNA vaccine candidates: alternative platforms for mRNA vaccine development","volume":"12","author":"Schmidt","year":"2023","journal-title":"Pathogens"},{"key":"2025090902071103800_EBC-2025-3009C19","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abo1827","article-title":"Structural and biochemical characteristics of mRNA nanoparticles determine anti-SARS-CoV-2 humoral and cellular immune responses","volume":"8","author":"Shi","year":"2022","journal-title":"Sci. Adv."},{"key":"2025090902071103800_EBC-2025-3009C20","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/s41590-022-01253-8","article-title":"Targeting TFH cells in human diseases and vaccination: rationale and practice","volume":"23","author":"Yu","year":"2022","journal-title":"Nat. Immunol."},{"key":"2025090902071103800_EBC-2025-3009C21","doi-asserted-by":"crossref","first-page":"111647","DOI":"10.1016\/j.celrep.2022.111647","article-title":"Chronic type I interferon signaling promotes lipid-peroxidation-driven terminal CD8+ T cell exhaustion and curtails anti-PD-1 efficacy","volume":"41","author":"Chen","year":"2022","journal-title":"Cell Rep."},{"key":"2025090902071103800_EBC-2025-3009C22","doi-asserted-by":"crossref","first-page":"115419","DOI":"10.1016\/j.addr.2024.115419","article-title":"Advances in the design and delivery of RNA vaccines for infectious diseases","volume":"213","author":"Lokras","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2025090902071103800_EBC-2025-3009C23","doi-asserted-by":"crossref","first-page":"103341","DOI":"10.1016\/j.drudis.2022.103341","article-title":"Self-amplifying mRNA vaccines: mode of action, design, development and optimization","volume":"27","author":"Pourseif","year":"2022","journal-title":"Drug Discov. Today"},{"key":"2025090902071103800_EBC-2025-3009C24","doi-asserted-by":"crossref","DOI":"10.3390\/nano10071424","article-title":"Lipid-based drug delivery nanoplatforms for colorectal cancer therapy","volume":"10","author":"Yang","year":"2020","journal-title":"Nanomaterials"},{"key":"2025090902071103800_EBC-2025-3009C25","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1038\/s41467-020-17409-9","article-title":"Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice","volume":"11","author":"McKay","year":"2020","journal-title":"Nat. Commun."},{"key":"2025090902071103800_EBC-2025-3009C26","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.coviro.2017.11.006","article-title":"Innate immune control of alphavirus infection","volume":"28","author":"Carpentier","year":"2018","journal-title":"Curr. Opin. Virol."},{"key":"2025090902071103800_EBC-2025-3009C27","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.941931","article-title":"Nucleic acid sensing by toll-like receptors in the endosomal compartment","volume":"13","author":"Miyake","year":"2022","journal-title":"Front. Immunol."},{"key":"2025090902071103800_EBC-2025-3009C28","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.molmed.2019.10.002","article-title":"Tailoring mRNA vaccine to balance innate\/adaptive immune response","volume":"26","author":"Linares-Fern\u00e1ndez","year":"2020","journal-title":"Trends Mol. Med."},{"key":"2025090902071103800_EBC-2025-3009C29","doi-asserted-by":"crossref","first-page":"114826","DOI":"10.1016\/j.addr.2023.114826","article-title":"Clinical delivery of circular RNA: lessons learned from RNA drug development","volume":"197","author":"Loan Young","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2025090902071103800_EBC-2025-3009C30","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.cell.2022.03.044","article-title":"Circular RNA vaccines against SARS-CoV-2 and emerging variants","volume":"185","author":"Qu","year":"2022","journal-title":"Cell"},{"key":"2025090902071103800_EBC-2025-3009C31","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41392-023-01561-x","article-title":"Circular RNA vaccine in disease prevention and treatment","volume":"8","author":"Niu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"2025090902071103800_EBC-2025-3009C32","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41587-022-01393-0","article-title":"Engineering circular RNA for enhanced protein production","volume":"41","author":"Chen","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"2025090902071103800_EBC-2025-3009C33","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.01775-23","article-title":"Circular RNA vaccines with long-term lymph node-targeting delivery stability after lyophilization induce potent and persistent immune responses","volume":"15","author":"Wan","year":"2024","journal-title":"mBio"},{"key":"2025090902071103800_EBC-2025-3009C34","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens13080692","article-title":"Advances in engineering circular RNA vaccines","volume":"13","author":"Zhang","year":"2024","journal-title":"Pathogens"},{"key":"2025090902071103800_EBC-2025-3009C35","doi-asserted-by":"crossref","first-page":"2308029","DOI":"10.1002\/adma.202308029","article-title":"Engineered mRNA delivery systems for biomedical applications","volume":"36","author":"Wang","year":"2024","journal-title":"Adv. Mater. Weinheim"},{"key":"2025090902071103800_EBC-2025-3009C36","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jconrel.2024.03.056","article-title":"mRNA therapies: pioneering a new era in rare genetic disease treatment","volume":"369","author":"Shen","year":"2024","journal-title":"J. Control. Release"},{"key":"2025090902071103800_EBC-2025-3009C37","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41573-023-00827-x","article-title":"Tailor made: the art of therapeutic mRNA design","volume":"23","author":"Metkar","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"2025090902071103800_EBC-2025-3009C38","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"2025090902071103800_EBC-2025-3009C39","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23052736","article-title":"Current advances in RNA therapeutics for human diseases","volume":"23","author":"Zogg","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"2025090902071103800_EBC-2025-3009C40","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines12060624","article-title":"Exploring the impact of mRNA modifications on translation efficiency and immune tolerance to self-antigens","volume":"12","author":"Sioud","year":"2024","journal-title":"Vaccines"},{"key":"2025090902071103800_EBC-2025-3009C41","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ymthe.2022.10.015","article-title":"N1-methyladenosine formation, gene regulation, biological functions, and clinical relevance","volume":"31","author":"Xiong","year":"2023","journal-title":"Mol. Ther."},{"key":"2025090902071103800_EBC-2025-3009C42","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s12032-019-1260-6","article-title":"Importance of m N6-methyladenosine (m6A) RNA modification in cancer","volume":"36","author":"Tuncel","year":"2019","journal-title":"Med. Oncol."},{"key":"2025090902071103800_EBC-2025-3009C43","article-title":"The pivotal role of chemical modifications in mRNA therapeutics","volume":"10","author":"Liu","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"2025090902071103800_EBC-2025-3009C44","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14071387","article-title":"Efficient induction of antigen-specific CD8+ T-cell responses by cationic peptide-based mRNA nanoparticles","volume":"14","author":"D\u2019haese","year":"2022","journal-title":"Pharmaceutics"},{"key":"2025090902071103800_EBC-2025-3009C45","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.drudis.2019.07.011","article-title":"Cervical cancer and HPV infection: ongoing therapeutic research to counteract the action of E6 and E7 oncoproteins","volume":"24","author":"Almeida","year":"2019","journal-title":"Drug Discov. Today"},{"key":"2025090902071103800_EBC-2025-3009C46","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9070734","article-title":"Detailed dissection and critical evaluation of the Pfizer\/BioNTech and moderna mRNA vaccines","volume":"9","author":"Xia","year":"2021","journal-title":"Vaccines"},{"key":"2025090902071103800_EBC-2025-3009C47","doi-asserted-by":"crossref","first-page":"168822","DOI":"10.1016\/j.jmb.2024.168822","article-title":"Engineered mRNAs with stable structures minimize double-stranded RNA formation and increase protein expression","volume":"436","author":"Qin","year":"2024","journal-title":"J. Mol. Biol."},{"key":"2025090902071103800_EBC-2025-3009C48","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1038\/s41467-023-38244-8","article-title":"Cap analogs with a hydrophobic photocleavable tag enable facile purification of fully capped mRNA with various cap structures","volume":"14","author":"Inagaki","year":"2023","journal-title":"Nat. Commun."},{"key":"2025090902071103800_EBC-2025-3009C49","doi-asserted-by":"crossref","first-page":"19845","DOI":"10.1038\/s41598-024-70792-x","article-title":"Optimization of the 5\u2019 untranslated region of mRNA vaccines","volume":"14","author":"Ma","year":"2024","journal-title":"Sci. Rep."},{"key":"2025090902071103800_EBC-2025-3009C50","doi-asserted-by":"crossref","first-page":"7792","DOI":"10.1093\/nar\/gkae510","article-title":"The impact of mRNA poly(A) tail length on eukaryotic translation stages","volume":"52","author":"Biziaev","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"2025090902071103800_EBC-2025-3009C51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13273-021-00171-4","article-title":"Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency","volume":"18","author":"Kim","year":"2022","journal-title":"Mol. Cell. Toxicol."},{"key":"2025090902071103800_EBC-2025-3009C52","doi-asserted-by":"crossref","first-page":"15231","DOI":"10.1021\/acsnano.2c12584","article-title":"The mRNA vaccine revolution: COVID-19 has launched the future of vaccinology","volume":"17","author":"Ye","year":"2023","journal-title":"ACS Nano"},{"key":"2025090902071103800_EBC-2025-3009C53","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1021\/acs.accounts.1c00621","article-title":"Machine learning for designing next-generation mRNA therapeutics","volume":"55","author":"Castillo-Hair","year":"2022","journal-title":"Acc. Chem. Res."},{"key":"2025090902071103800_EBC-2025-3009C54","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/s41586-023-06127-z","article-title":"Algorithm for optimized mRNA design improves stability and immunogenicity","volume":"621","author":"Zhang","year":"2023","journal-title":"Nature"},{"key":"2025090902071103800_EBC-2025-3009C55","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.108015","article-title":"mRNA vaccine sequence and structure design and optimization: advances and challenges","volume":"301","author":"Jin","year":"2025","journal-title":"J. Biol. Chem."},{"key":"2025090902071103800_EBC-2025-3009C56","doi-asserted-by":"crossref","first-page":"5315","DOI":"10.1021\/acs.jctc.3c00513","article-title":"Computational methods in immunology and vaccinology: design and development of antibodies and immunogens","volume":"19","author":"Guarra","year":"2023","journal-title":"J. Chem. Theory Comput."},{"key":"2025090902071103800_EBC-2025-3009C57","doi-asserted-by":"crossref","first-page":"108395","DOI":"10.1016\/j.biotechadv.2024.108395","article-title":"Development and applications of lipid hydrophilic headgroups for nucleic acid therapy","volume":"74","author":"Ma","year":"2024","journal-title":"Biotechnol. Adv."},{"key":"2025090902071103800_EBC-2025-3009C58","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.actbio.2022.09.065","article-title":"Development of amino acid-modified biodegradable lipid nanoparticles for siRNA delivery","volume":"154","author":"Patel","year":"2022","journal-title":"Acta Biomater."},{"key":"2025090902071103800_EBC-2025-3009C59","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jconrel.2021.01.005","article-title":"Novel lipid combination for delivery of plasmid DNA to immune cells in the spleen","volume":"330","author":"Kimura","year":"2021","journal-title":"J. Control. Release"},{"key":"2025090902071103800_EBC-2025-3009C60","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"2025090902071103800_EBC-2025-3009C61","first-page":"86","article-title":"Engineering LNPs with polysarcosine lipids for mRNA delivery","volume":"37","author":"Kang","year":"2024","journal-title":"Bioact. Mater."},{"key":"2025090902071103800_EBC-2025-3009C62","doi-asserted-by":"crossref","first-page":"6488","DOI":"10.1016\/j.vaccine.2023.05.062","article-title":"Evaluation of a stabilized RSV pre-fusion F mRNA vaccine: preclinical studies and phase 1 clinical testing in healthy adults","volume":"41","author":"Nussbaum","year":"2023","journal-title":"Vaccine"},{"key":"2025090902071103800_EBC-2025-3009C63","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S1473-3099(23)00650-3","article-title":"Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial","volume":"24","author":"Oda","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"2025090902071103800_EBC-2025-3009C64","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.1016\/S2666-5247(21)00280-9","article-title":"Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"3","author":"Chen","year":"2022","journal-title":"Lancet Microbe"},{"key":"2025090902071103800_EBC-2025-3009C65","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"2025090902071103800_EBC-2025-3009C66","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41551-023-01082-6","article-title":"Enhancing the immunogenicity of lipid-nanoparticle mRNA vaccines by adjuvanting the ionizable lipid and the mRNA","volume":"9","author":"Li","year":"2025","journal-title":"Nat. Biomed. Eng."},{"key":"2025090902071103800_EBC-2025-3009C67","article-title":"mRNA vaccines against SARS-CoV-2 variants delivered by lipid nanoparticles based on novel ionizable lipids","volume":"32","author":"Chen","year":"2022","journal-title":"Adv. Funct. Mater."},{"key":"2025090902071103800_EBC-2025-3009C68","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1021\/acs.accounts.1c00544","article-title":"Chemistry of lipid nanoparticles for RNA delivery","volume":"55","author":"Eygeris","year":"2022","journal-title":"Acc. Chem. Res."},{"key":"2025090902071103800_EBC-2025-3009C69","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/s41467-020-14527-2","article-title":"Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA","volume":"11","author":"Patel","year":"2020","journal-title":"Nat. Commun."},{"key":"2025090902071103800_EBC-2025-3009C70","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1039\/D1BM01454D","article-title":"Optimization of phospholipid chemistry for improved lipid nanoparticle (LNP) delivery of messenger RNA (mRNA)","volume":"10","author":"\u00c1lvarez-Benedicto","year":"2022","journal-title":"Biomater. Sci."},{"key":"2025090902071103800_EBC-2025-3009C71","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s12951-022-01478-7","article-title":"Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects","volume":"20","author":"Kiaie","year":"2022","journal-title":"J. Nanobiotechnology"},{"key":"2025090902071103800_EBC-2025-3009C72","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1186\/s12951-024-02812-x","article-title":"Role of size, surface charge, and PEGylated lipids of lipid nanoparticles (LNPs) on intramuscular delivery of mRNA","volume":"22","author":"Kong","year":"2024","journal-title":"J. Nanobiotechnology"},{"key":"2025090902071103800_EBC-2025-3009C73","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1111\/ajt.16516","article-title":"Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine - United States, December 14-23, 2020","volume":"21","author":"Shimabukuro","year":"2021","journal-title":"Am. J. Transplant."},{"key":"2025090902071103800_EBC-2025-3009C74","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1021\/bc200551b","article-title":"Role of the methoxy group in immune responses to mPEG-protein conjugates","volume":"23","author":"Sherman","year":"2012","journal-title":"Bioconjug. Chem."},{"key":"2025090902071103800_EBC-2025-3009C75","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.cmi.2021.10.005","article-title":"Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review","volume":"28","author":"Fiolet","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"2025090902071103800_EBC-2025-3009C76","article-title":"Hydroxy polyethylene glycol: a solution to evade human pre-existing anti-PEG antibodies for efficient delivery","volume":"2024.2010. 2021.619346","author":"Ding","year":"2024","journal-title":"bioRxiv"},{"key":"2025090902071103800_EBC-2025-3009C77","first-page":"1","article-title":"High-density brush-shaped polymer lipids reduce anti-PEG antibody binding for repeated administration of mRNA therapeutics","author":"Xiao","year":"2025","journal-title":"Nat. Mater."},{"key":"2025090902071103800_EBC-2025-3009C78","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41541-021-00292-w","article-title":"SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates","volume":"6","author":"Kyriakidis","year":"2021","journal-title":"NPJ Vaccines"},{"key":"2025090902071103800_EBC-2025-3009C79","article-title":"Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study","volume":"375","author":"Bruxvoort","year":"2021","journal-title":"BMJ"},{"key":"2025090902071103800_EBC-2025-3009C80","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.vaccine.2024.01.098","article-title":"Immunogenicity and safety of A SARS-CoV-2 mRNA vaccine (SYS6006) in healthy Chinese participants: a randomized, observer-blinded, placebo-controlled phase 2 clinical trial","volume":"42","author":"Jin","year":"2024","journal-title":"Vaccine"},{"key":"2025090902071103800_EBC-2025-3009C81","article-title":"A novel mRNA vaccine, SYS6006, against SARS-CoV-2","volume":"13","author":"Xu","year":"2022","journal-title":"Front. Immunol."},{"key":"2025090902071103800_EBC-2025-3009C82","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2024.1468775","article-title":"Safety and immunogenicity of a SARS-CoV-2 mRNA vaccine (SYS6006) in minks, cats, blue foxes, and raccoon dogs","volume":"14","author":"Huo","year":"2024","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"2025090902071103800_EBC-2025-3009C83","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1080\/10837450.2024.2361656","article-title":"mRNA-based vaccines - global approach, challenges, and could be a promising wayout for future pandemics","volume":"29","author":"Makhijani","year":"2024","journal-title":"Pharm. Dev. Technol."},{"key":"2025090902071103800_EBC-2025-3009C84","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14122682","article-title":"Recent advances in lipid nanoparticles for delivery of mRNA","volume":"14","author":"Yang","year":"2022","journal-title":"Pharmaceutics"},{"key":"2025090902071103800_EBC-2025-3009C85","article-title":"Towards broad-spectrum protection: the development and challenges of combined respiratory virus vaccines","volume":"14","author":"Wang","year":"2024","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"2025090902071103800_EBC-2025-3009C86","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines12121382","article-title":"Advantages of broad-spectrum influenza mRNA vaccines and their impact on pulmonary influenza","volume":"12","author":"Cheng","year":"2024","journal-title":"Vaccines"},{"key":"2025090902071103800_EBC-2025-3009C87","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1038\/s41467-024-47905-1","article-title":"Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: pooled phase 1, 2, 3a and 3b randomized, controlled trials","volume":"15","author":"H\u1ed3","year":"2024","journal-title":"Nat. Commun."},{"key":"2025090902071103800_EBC-2025-3009C88","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S1473-3099(24)00060-4","article-title":"Persistence of immune responses of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2","volume":"24","author":"Oda","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"2025090902071103800_EBC-2025-3009C89","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2025090902071103800_EBC-2025-3009C90","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2107456","article-title":"Safety, immunogenicity, and efficacy of the BNT162b2 COVID-19 vaccine in adolescents","volume":"385","author":"Frenck","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"2025090902071103800_EBC-2025-3009C91","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1056\/NEJMoa2104983","article-title":"Preliminary findings of mRNA COVID-19 vaccine safety in pregnant persons","volume":"384","author":"Shimabukuro","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"2025090902071103800_EBC-2025-3009C92","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine through 6 months","volume":"385","author":"Thomas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"2025090902071103800_EBC-2025-3009C93","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-018-0002-y","article-title":"Influenza","volume":"4","author":"Krammer","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"2025090902071103800_EBC-2025-3009C94","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1038\/s41467-023-39376-7","article-title":"Safety and immunogenicity of a phase 1\/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis","volume":"14","author":"Lee","year":"2023","journal-title":"Nat. Commun."},{"key":"2025090902071103800_EBC-2025-3009C95","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1093\/infdis\/jiae329","article-title":"Safety and immunogenicity of mRNA-1010, an investigational seasonal influenza vaccine, in healthy adults: final results from a phase 1\/2 randomized trial","volume":"231","author":"Ananworanich","year":"2025","journal-title":"J. Infect. Dis."},{"key":"2025090902071103800_EBC-2025-3009C96","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/s41573-024-01042-y","article-title":"mRNA vaccines for infectious diseases - advances, challenges and opportunities","volume":"23","author":"Pardi","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"2025090902071103800_EBC-2025-3009C97","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3390\/vaccines13030304","article-title":"Progress on respiratory syncytial virus vaccine development and evaluation methods","volume":"13","author":"Deng","year":"2025","journal-title":"Vaccines"},{"key":"2025090902071103800_EBC-2025-3009C98","doi-asserted-by":"crossref","first-page":"e747","DOI":"10.1016\/S1473-3099(24)00455-9","article-title":"The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access","volume":"24","author":"Terstappen","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"2025090902071103800_EBC-2025-3009C99","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.resinv.2024.08.011","article-title":"Safety and immunogenicity of an mRNA-based RSV vaccine in Japanese older adults aged \u226560 years: a phase 1, randomized, observer-blind, placebo-controlled trial","volume":"62","author":"Fitz-Patrick","year":"2024","journal-title":"Respir. Investig."},{"key":"2025090902071103800_EBC-2025-3009C100","article-title":"FDA pauses all infant RSV vaccine trials after rise in severe illnesses","volume":"387","author":"Mahase","year":"2024","journal-title":"BMJ"},{"key":"2025090902071103800_EBC-2025-3009C101","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1172691","article-title":"mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV","volume":"14","author":"Matarazzo","year":"2023","journal-title":"Front. Immunol."},{"key":"2025090902071103800_EBC-2025-3009C102","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1016\/S2352-3018(23)00264-3","article-title":"Prophylactic HIV-1 vaccine trials: past, present, and future","volume":"11","author":"Nkolola","year":"2024","journal-title":"Lancet HIV"},{"key":"2025090902071103800_EBC-2025-3009C103","doi-asserted-by":"crossref","DOI":"10.2196\/53375","article-title":"Public discourse, user reactions, and conspiracy theories on the X platform about HIV vaccines: data mining and content analysis","volume":"26","author":"Zhang","year":"2024","journal-title":"J. Med. Internet Res."},{"key":"2025090902071103800_EBC-2025-3009C104","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41587-022-01294-2","article-title":"The clinical progress of mRNA vaccines and immunotherapies","volume":"40","author":"Barbier","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"2025090902071103800_EBC-2025-3009C105","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41541-023-00656-4","article-title":"An optimized messenger RNA vaccine candidate protects non-human primates from Zika virus infection","volume":"8","author":"Bollman","year":"2023","journal-title":"NPJ Vaccines"},{"key":"2025090902071103800_EBC-2025-3009C106","doi-asserted-by":"crossref","first-page":"e668","DOI":"10.1093\/infdis\/jiae114","article-title":"Safety and immunogenicity of a messenger RNA-based cytomegalovirus vaccine in healthy adults: results from a phase 1 randomized clinical trial","volume":"230","author":"Fierro","year":"2024","journal-title":"J. Infect. Dis."},{"key":"2025090902071103800_EBC-2025-3009C107","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/infdis\/jiad593","article-title":"Human cytomegalovirus mRNA-1647 vaccine candidate elicits potent and broad neutralization and higher antibody-dependent cellular cytotoxicity responses than the gB\/MF59 vaccine","volume":"230","author":"Hu","year":"2024","journal-title":"J. Infect. Dis."},{"key":"2025090902071103800_EBC-2025-3009C108","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines11091452","article-title":"Malaria vaccines: from the past towards the mRNA vaccine era","volume":"11","author":"Tsoumani","year":"2023","journal-title":"Vaccines"},{"key":"2025090902071103800_EBC-2025-3009C109","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.789427","article-title":"The critical contribution of pseudouridine to mRNA COVID-19 vaccines","volume":"9","author":"Morais","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"2025090902071103800_EBC-2025-3009C110","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0140-6736(17)31665-3","article-title":"Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial","volume":"390","author":"Alberer","year":"2017","journal-title":"The Lancet"},{"key":"2025090902071103800_EBC-2025-3009C111","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032700","article-title":"A comprehensive review of mRNA vaccines","volume":"24","author":"Gote","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"2025090902071103800_EBC-2025-3009C112","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.xphs.2020.12.006","article-title":"Addressing the cold reality of mRNA vaccine stability","volume":"110","author":"Crommelin","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"2025090902071103800_EBC-2025-3009C113","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1039\/D2BM02031A","article-title":"Successful batch and continuous lyophilization of mRNA LNP formulations depend on cryoprotectants and ionizable lipids","volume":"11","author":"Lamoot","year":"2023","journal-title":"Biomater. Sci."},{"key":"2025090902071103800_EBC-2025-3009C114","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1016\/j.xphs.2020.07.015","article-title":"Freeze-drying of pharmaceutical and nutraceutical nanoparticles: the effects of formulation and technique parameters on nanoparticles characteristics","volume":"109","author":"Mohammady","year":"2020","journal-title":"J. Pharm. Sci."},{"key":"2025090902071103800_EBC-2025-3009C115","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/j.ymthe.2022.02.001","article-title":"Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine","volume":"30","author":"Muramatsu","year":"2022","journal-title":"Mol. Ther."},{"key":"2025090902071103800_EBC-2025-3009C116","doi-asserted-by":"crossref","DOI":"10.1038\/s41421-022-00517-9","article-title":"Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2","volume":"9","author":"Ai","year":"2023","journal-title":"Cell Discov."},{"key":"2025090902071103800_EBC-2025-3009C117","doi-asserted-by":"crossref","first-page":"2450045","DOI":"10.1080\/21645515.2025.2450045","article-title":"The mRNA-1647 vaccine: a promising step toward the prevention of cytomegalovirus infection (CMV)","volume":"21","author":"Akingbola","year":"2025","journal-title":"Hum. Vaccin. Immunother."},{"key":"2025090902071103800_EBC-2025-3009C118","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.xphs.2024.12.013","article-title":"Recent advances in drying and development of solid formulations for stable mRNA and siRNA lipid nanoparticles","volume":"114","author":"Arte","year":"2025","journal-title":"J. Pharm. Sci."},{"key":"2025090902071103800_EBC-2025-3009C119","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.1039\/D3TB02766J","article-title":"Lipid nanoparticles as the drug carrier for targeted therapy of hepatic disorders","volume":"12","author":"Chu","year":"2024","journal-title":"J. Mater. Chem. B"},{"key":"2025090902071103800_EBC-2025-3009C120","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202305300","article-title":"Lipid nanoparticles optimized for targeting and release of nucleic acid","volume":"36","author":"Jia","year":"2024","journal-title":"Adv. Mater. Weinheim"},{"key":"2025090902071103800_EBC-2025-3009C121","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"2025090902071103800_EBC-2025-3009C122","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14102129","article-title":"Delivery of RNAs to specific organs by lipid nanoparticles for gene therapy","volume":"14","author":"Godbout","year":"2022","journal-title":"Pharmaceutics"},{"key":"2025090902071103800_EBC-2025-3009C123","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15041184","article-title":"Key design features of lipid nanoparticles and electrostatic charge-based lipid nanoparticle targeting","volume":"15","author":"Gyanani","year":"2023","journal-title":"Pharmaceutics"},{"key":"2025090902071103800_EBC-2025-3009C124","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41525-023-00387-4","article-title":"Breaking the mold with RNA-a \u201cRNAissance\u201d of life science","volume":"9","author":"Jones","year":"2024","journal-title":"NPJ Genom. Med."}],"container-title":["Essays in Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/essaysbiochem\/article-pdf\/69\/02\/109\/972480\/ebc-2025-3009.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/essaysbiochem\/article-pdf\/69\/02\/109\/972480\/ebc-2025-3009.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T06:08:16Z","timestamp":1757398096000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/essaysbiochem\/article\/69\/02\/109\/236013\/Advancing-mRNA-vaccines-for-infectious-diseases"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":124,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2025,5,1]]},"published-print":{"date-parts":[[2025,9,8]]}},"URL":"https:\/\/doi.org\/10.1042\/ebc20253009","relation":{},"ISSN":["0071-1365","1744-1358"],"issn-type":[{"value":"0071-1365","type":"print"},{"value":"1744-1358","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,5,1]]}}}